GENFIT
Develops therapies and diagnostics for patients with rare and severe liver diseases.
GNFT | PA
Overview
Corporate Details
- ISIN(s):
- FR0004163111 (+2 more)
- LEI:
- 969500XPWN2DMZQA5X73
- Country:
- France
- Address:
- 885 AVENUE EUGENE AVINEE, 59120 LOOS
- Website:
- https://www.genfit.com
Description
GENFIT is a biopharmaceutical company dedicated to developing therapeutic and diagnostic solutions for patients with rare and severe liver diseases characterized by high unmet medical needs. The company's primary focus is on Acute-on-Chronic Liver Failure (ACLF) and its associated conditions, such as acute decompensation (AD) and hepatic encephalopathy (HE). Leveraging a scientific heritage of over two decades, GENFIT is a pioneer in liver disease research and development, aiming to improve the lives of patients with these life-threatening conditions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-01-13 22:10 |
GENFIT : Bilan semestriel du contrat de liquidité contracté avec le Crédit Indu…
|
French | 268.7 KB | ||
| 2024-11-07 22:10 |
GENFIT Reports Third Quarter 2024 Financial Information
|
English | 199.9 KB | ||
| 2024-09-19 22:10 |
GENFIT : Résultats financiers du premier semestre 2024 et point sur les activit…
|
French | 472.3 KB | ||
| 2024-09-19 22:10 |
GENFIT Reports First Half-Year 2024 Financial Results and Provides Corporate U…
|
English | 489.9 KB | ||
| 2024-09-19 22:00 |
Rapport d'activité et financier semestriel 2024 - Rapport des Commissaires aux …
|
French | 704.1 KB | ||
| 2024-07-26 13:45 |
GENFIT: Positive Opinion from EMA Committee for Ipsen’s Iqirvo® (elafibranor) i…
|
English | 149.0 KB | ||
| 2024-07-26 13:45 |
GENFIT : Avis positif du Comité des médicaments à usage humain (CHMP) pour l’Iq…
|
French | 135.1 KB | ||
| 2024-07-09 22:10 |
GENFIT : Bilan semestriel du contrat de liquidité contracté avec le Crédit Indu…
|
French | 283.0 KB | ||
| 2024-07-09 22:10 |
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commer…
|
English | 293.1 KB | ||
| 2024-06-17 22:10 |
GENFIT : Les nouvelles recommandations de pratique clinique de l'EASL-EASD-EASO…
|
French | 186.1 KB | ||
| 2024-06-17 22:10 |
GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+…
|
English | 187.5 KB | ||
| 2024-06-10 23:22 |
GENFIT : Étape historique franchie avec l'approbation accélérée d'Iqirvo® d’Ips…
|
French | 340.0 KB | ||
| 2024-06-10 23:22 |
GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen…
|
English | 193.2 KB | ||
| 2024-05-29 22:10 |
GENFIT to Present Latest ACLF Research at EASL Congress™ 2024
|
English | 182.0 KB | ||
| 2024-05-29 22:10 |
GENFIT présentera ses dernières avancées dans l'ACLF à l'EASL Congress™ 2024
|
French | 175.7 KB |
Automate Your Workflow. Get a real-time feed of all GENFIT filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for GENFIT
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for GENFIT via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-07-07 | N/A | Other | Buy | 5,300 | 19,488.10 EUR |
| 2023-07-06 | N/A | Other | Buy | 1,100 | 4,048.00 EUR |
| 2023-07-05 | N/A | Other | Buy | 10,000 | 37,061.00 EUR |
| 2023-07-03 | N/A | Other | Buy | 5,300 | 18,769.95 EUR |
Peer Companies
